Disruptions in Amino Acid, Lipid Metabolism May Signal Tardive Dyskinesia
By Elana Gotkine HealthDay Reporter
THURSDAY, March 20, 2025 -- Disruptions in amino acid and lipid metabolism may be biomarkers of tardive dyskinesia (TD), according to a study published online Feb. 21 in Schizophrenia Bulletin.
Chenghao Lu, from the Mental Health Center of Tianjin Medical University in China, and colleagues explored biomarkers of TD through untargeted metabolomics for the early identification of TD in a study involving 84 patients with schizophrenia (SZ) with TD and 160 patients with SZ without TD. Fasting blood samples were collected from all patients; 699 metabolites were quantified and profiled.
The researchers found that 57 metabolites exhibited significant changes in TD, mainly involving amino acids and lipids. These changes mostly affected the phenylalanine, tyrosine, and tryptophan pathway and the phenylalanine metabolism pathway. Negative relations to the total abnormal involuntary movement scale score were seen for N-acetyl-L-phenylalanine and succinylcarnitine. Five differential metabolites had area under the curve (AUC) values greater than 0.7 for diagnosing TD, with a combined AUC of 0.817.
"These findings provide possible biomarkers for the diagnosis of TD, facilitating early recognition of TD," the authors write. "However, these preliminary results require validation in larger sample sizes and longitudinal studies."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted March 2025
Read this next
Hydrops MRI Accurately Differentiates Meniere Disease, Vestibular Migraine
MONDAY, June 23, 2025 -- The combination of cochlear endolymphatic hydrops (CEH) and vestibular endolymphatic hydrops (VEH) on magnetic resonance imaging (MRI) accurately...
Gluten-Stimulated Interleukin-2 Secretion Useful for Diagnosing Celiac Disease
MONDAY, June 23, 2025 -- Gluten-stimulated interleukin-2 (IL-2) secretion is useful for diagnosis of celiac disease (CeD), according to a study published online June 9 in...
Minor Complications Up for Black Patients After Weight-Loss Surgery
MONDAY, June 23, 2025 -- Black patients have a higher incidence of minor complications after metabolic and bariatric surgery, according to a study presented at the annual meeting...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.